Title:
HETEROBICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Document Type and Number:
WIPO Patent Application WO/2024/019562
Kind Code:
A1
Abstract:
The present invention relates to a heterobicyclic compound that exhibits inhibitory activity against TEAD transcriptional activation by inhibiting the binding of YAP or TAZ to TEAD, and a pharmaceutical composition comprising same as an active ingredient. The heterobicyclic compound of the present invention can be advantageously used in the treatment or prevention of cancer.
Inventors:
KIM JINHYUK (KR)
KIM YONG CHAN (KR)
MOON SUNGHO (KR)
KIM MINHYE (KR)
CHO SEONYEON (KR)
LEE IN SANG (KR)
NO KYOUNG TAI (KR)
PIAO CHENGRI (KR)
KIM HAN SEONG (KR)
KIM YONG CHAN (KR)
MOON SUNGHO (KR)
KIM MINHYE (KR)
CHO SEONYEON (KR)
LEE IN SANG (KR)
NO KYOUNG TAI (KR)
PIAO CHENGRI (KR)
KIM HAN SEONG (KR)
Application Number:
PCT/KR2023/010500
Publication Date:
January 25, 2024
Filing Date:
July 20, 2023
Export Citation:
Assignee:
BAOBAB AIBIO CO LTD (KR)
International Classes:
C07D217/26; A61K31/472; A61P35/00; C07D217/02
Domestic Patent References:
| WO2022072741A1 | 2022-04-07 | |||
| WO2017190109A1 | 2017-11-02 | |||
| WO2020243423A1 | 2020-12-03 | |||
| WO2021186324A1 | 2021-09-23 |
Other References:
KURPPA KARI J.; LIU YAO; TO CIRIC; ZHANG TINGHU; FAN MENGYANG; VAJDI AMIR; KNELSON ERIK H.; XIE YINGTIAN; LIM KLOTHILDA; CEJAS PAL: "Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway", CANCER CELL, CELL PRESS, US, vol. 37, no. 1, 13 January 2020 (2020-01-13), US , pages 104, XP085985354, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2019.12.006
Attorney, Agent or Firm:
YU, Su Mi (KR)
Download PDF:
Previous Patent: BANDGAP REFERENCE VOLTAGE GENERATION CIRCUIT AND SEMICONDUCTOR DEVICE INCLUDING SAME
Next Patent: VEHICLE WHEEL BEARING
Next Patent: VEHICLE WHEEL BEARING